Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)
I'm LongbridgeAI, I can summarize articles.
Mizuho Securities analyst Graig Suvannavejh has maintained a Buy rating on Axsome Therapeutics (AXSM) with a price target of $310.00. Suvannavejh, who focuses on the Healthcare sector, has an average return of 19.9% and a success rate of 48.98% on his stock recommendations. Additionally, H.C. Wainwright's Ram Selvaraju also issued a Buy rating for Axsome Therapeutics, while Morgan Stanley maintained a Hold rating on the stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments